Viral Hepatitis Flashcards

1
Q

Transmission of Hep A

A

Fecal Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Transmission of Hep B

A

Parental
Sexual
Perinatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HAV risk factors

A

Travelers to high risk countries/endemic areas
Contacts of recent international adoptees from HAV endemic countries
Household and sexual contacts
Men who have sex with men
Persons who inject drugs
work with HAV infected primates
Food outbreaks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HBV risk factors

A

Born to infected mothers
Multiple sex partners
STIs
MSM
IVDU
Household contacts
Healthcare workers, public safety workers, residents and staff of facilities for developmentally disabled persons
Hemodialysis
Travel to region with high prevalence of HBV
Healthcare-associated outbreaks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HCV risk factors

A

IVDU
MSM
STI
Blood transfusion
Needle stick injuries
Tattoos in nonregulated settings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cirrhosis:
Detection use what?
Severity can be determined by what?
Compensated?
Decompensated?

A

US of liver; Blood tests
Child Turcotte Pugh score
Child Pugh A
Child Pugh B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical Presentation of Viral Hepatitis Acute

A

Fever
Fatigue
Loss of appetite
Nausea
Vomiting
Abdominal Pain
Gray-colored bowel movements
Joint pain
Jaundice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Viral Hepatitis
VAH
Acute?
Immunity?
Total =?

A

Anti-HAV IgM
Anti-HAV Ab (or HAV Ab)
IgG + IgM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Viral Hepatitis
HBV
Immunity? (Vaccine) (Past Infection)?
Acute?
Chronic?
Infectious?

A

Anti-HBs (or HBsAb) (+) 10 mlU/mL; (HBcAb -); (HBcAb +)
HBsAg (+) and HBcAb (+) and HBcAb IgM (+)
HBsAg (+) and HBcAb (+) (total = IgG + IgM)
HBeAg (+) and HBV DNA (viral load)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Viral Hepatitis
HCV
Screen?
Chronic?

A

HCV Ab
HCV RNA (viral load) detectable x 6 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HBV DNA undetectable level = ?
HCV RNA undetectable level = ?

A

< 20
< 15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HBV status
HBsAg (Neg)
anti-HBc (Neg)
anti-HBs (Neg)

A

Susceptible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HBV status
HBsAg (Neg)
anti-HBc (Pos)
anti-HBs (POS)

A

Immune due to natural infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HBV status
HBsAg (Neg)
anti-HBc (Neg)
anti-HBs (Pos)

A

Immune due to hepatitis B vaccination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HBV status
HBsAg (Pos)
anti-HBc (Pos)
IgM anti-HBc (Pos)
anti-HBs (Neg)

A

Acutely Infected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HBV status
HBsAg (Pos)
anti-HBc (Pos)
IgM anti-HBc (Neg)
anti-HBs (Neg)

A

Chronically Infected

17
Q

HBV status
HBsAg (Neg)
anti-HBc (Pos)
anti-HBs (Neg)

A

Interpretation unclear; four possibilities
1. Resolved infection (most common)
2. False-positive anti-HBc, thus susceptible
3. “Low level” chronic infection
4. Resolving acute infection

18
Q

Viral Hepatitis Acute Treatement

A

Supportive Care

19
Q

Viral Hepatitis Chronic Treatment for which viruses?
Baseline testing includes what?

A

HBV; HCV
Viral load for HBV DNA; HCV RNA; HIV test prior to treating viral hepatitis

20
Q

HBV Goals of Treatment
Suppress what?
Loss of what?
Prevent what?

A

HBV replication (HBV DNA undetectable; < 20 IU/mL)
HBsAg
Progression

21
Q

Chronic HBV treatment Nucleoside/tide analogs
Disoproxil fumarate
Dose?
Adjustments for what/
Drug-drug interactions?
ADRs?

A

300mg PO daily
renal insufficiency
minimal
Nephrotoxicity (Monitor CrCl, serum phosphate, urine glucose and protein annually)
Decreased bone mineral density (consider BMD)

22
Q

Chronic HBV treatment Nucleoside/tide analogs
Alafenadmide
Dose?
Avoid use if?
what type of substrate?
Active against what strains?

A

25mg PO daily
CrCl < 15
P-glycoprotein
Iamivudine-resistant

23
Q

Chronic HBV treatment Nucleoside/tide analogs
Entecavir
Dose: Naive, Lamivudine-resistant HBV?
Adjust dose in what?
Drug-drug interactions?
Tolerated how?
Effective against what?

A

Naive: 0.5mg PO daily
Lamivudine-resistant HBV: 1mg by mouth once daily
Adjust in renal insufficiency
Minimal
Relatively well
Iamivudine-resistant HBV

24
Q

Chronic HBV treatment Nucleoside/tide analogs
Lamivudine
Dose?
Adjust for what?
Tolerated how?
Drug-drug interactions?
High rates of what develop?

A

100mg PO daily
renal insufficiency
relatively well
minimal
resistance

25
Chronic HBV treatment Nucleoside/tide analogs Telbivudine Competitive inhibitor of what? Dose? Adjust in what? ADRs? High rates of what develop? Cross-resistance with what? It has an undefined what?
RT and DNA polymerase 600mg PO daily renal insufficiency Increased CK, myopathy, peripheral neuropathy resistance iamivudine role
26
Chronic HBV treatment duration HBeAg(+): HBeAg(-):
6mo following HBeAg seroconversion and HBV DNA undetectable indicates that HBV is in restful state. Occurs in acute hepatitis when antigen declines, virus becomes undetectable and HBeAB becomes (+)
27
HCV monitoring How often? What labs? Goal?
4 weeks and completion of therapy CMP, CBC, HCV RNA cure = sustained virological response (SVR), HCV RNA < 15
28
Viral Hepatitis Non-pharmacological treatment Avoid what? Vaccinate against what? What are risk factors for progression of HCV?
alcohol HAV and HBV as appropriate obesity, tobacco smoking, and marijuana
29
Viral Hepatitis Prevention Pharmacological? NonPharmacological: HAV? HBV? HCV? Occupational?
Vaccine: HAV HBV Handwashing none Do not share razors or toothbrushes standard precautions
30
HAV Vaccine Adult Recommended for the following populations?
Chronic liver dz Clotting factor dz MSM Drug Use Homelessness Work with HAV in research lab or with infected nonhuman primates Travelers to countries with intermediate to high endemic HAV Close personal contact with international adoptee arriving from intermediate to high endemic with HAV
31
HBV Vaccine Adult Recommended for the following populations?
HCV Chronic liver dz HIV Sexual exposure risk, partner (MSM, STI, not in mutually monogamous relationship) Current or past injection drug use incarcerated travelers to countries with intermediate to high endemic HBV DM